Sixty patients at the age of 43 to 79 years with anxiodepressive symptoms with comorbid cardiovascular disease have been examined after admission to psychotherapeutic department. Patients have been divided into two groups. The first group including 30patients were treated by the tricyclic antidepressant amitriptyline with the average daily dose of 34.4±12.9mg. The 30 patients from the second group were treated by antidepressants of the selective serotonin reuptake inhibitors group. The sociodemographic characteristics in both groups did not differ significantly; the sever-ity of cardiovascular disease, additional somatic and other diseases were certainty lower in the first group than in the second (p<0.05). Examination of the patients with the use of Hamilton Depression Rating Scale and Hamilton Anxiety Rating Scale (HDRS and HARS) was carried out three times: at admission, in 1 week and in 4 weeks. At the time of admission, anxiety and depression in the first group were more expressed (p<0.05) than in the second due to frequent psychogeny. The treatment scheme included tranquilizers, neuroleptics, neurometabolic drugs, basic cardiotropic therapy and psychotherapy. After 4 weeks anxiodepressive symptoms were more than 50% reduced in both groups: 61% in the first group and 50.7% in the second group by the HDRC scale; 65.9% in the first group and 59.8% in the second group by the HARS scale. It has been shown that the small doses of antidepressant including amitriptyline involved in the complex treatment scheme were efficient and did not cause cardiotoxic effect
tricyclic antidepressants, anxiodepressive disorders, cardiovascular disease
1. BaranovAP, StrutynskyAV, OynotkinovaOS,GorbachevaEV, TrishinaVV, Gusev-ShcherbakovAS,GolubevYY (2016). Effectiveness of treatment of patients with chronic heart failure and depressive disorders with nootropic drug Pantogam Active [Effektivnost’ lecheniya nootropnym preparatom Pantogam-aktiv patsientov s khronicheskoy serdechnoy nedostatochnost’yu i depressivnymi rasstroystvami]. Arkhiv vnutrenney meditsiny, 1(27), 54-62.
2. GolitsynSP, KropachevaES, MaikovEB, MironovNY, PanchenkoEP, SokolovSF, ShlevkovNB (2014). National clinical guidelines: Diagnostics and management of cardiac arrhythmias. Part II [Klinicheskie rekomendatsii: diagnostika i lechenie narusheniy ritma serdtsa i provodimosti. Chast’ II]. Kardiologicheskiy vestnik, (3), 3-52.
3. IvanetsNN, KinkulkinaMA, TikhonovaUG, AvdeevaTI,RagimovAA, DashkovaNG, KuznetsovOE, MatveevAV(2015). Evaluation of the prognostic significance of CYP2D6 genetic changes in the development of side effects of antidepressant treatment [Otsenka prognosticheskoy znachimosti geneticheskikh izmeneniy CYP2D6 pri razvitii pobochnykh effektov antidepressivnogo lecheniya]. Zhurnal «Psikhiatriya i psikhofarmakoterapiya» im. P.B. Gannushkina, 17(5-6), 46-51.
4. KopylovFU (2013). Diagnosis and treatment of depressive disorders in cardiology practice [Diagnostika i lechenie depressivnykh rasstroystv v kardiologicheskoy praktike]. Klinitsist, (2), 81-87.
5. LusovVA, VolovNA, LebedevaAY, BenevskayaMA, KudinovaMA (2010). Methods of diagnostics of anxiety and depressive disorders in patients with acute myocardial infarction [Metody diagnostiki trevozhno-depressivnykh rasstroystv u bol’nykh ostrym infarktom miokarda]. Rossiyskiy kardiologicheskiy zhurnal, (1), 77-81.
6. MakarovRB, LashkovaAA, ErmolaevaNA (2015). Evaluating the effectiveness of the use of agomelatine (agomelatine) in the treatment of cardiovascular diseases [Otsenka effektivnosti ispol’zovaniya val’doksana (agomelatina) pri lechenii serdechno-sosudistykh zabolevaniy]. Zdravookhranenie Dal’nego Vostoka, (2), 48-51.
7. MedvedevVE (2012). Prevention and therapy of psy-chopathological disorders in patients with cardiovascular diseases [Profilaktika i terapiya psikhopatologicheskikh rasstroystv u patsientov s serdechno-sosudistymi zabolevaniyami]. Nevrologiya, neyropsikhiatriya, psikhosomatika, 4(3), 54-59.
8. NikolaevEL, LazarevEY (2015). Psychotherapy and psychological care to patients with cardiovascular diseases [Psikhoterapiya i psikhologicheskaya pomoshch’ bol’nym serdechno-sosudistymi zabolevaniyami]. Vestnik psikhiatrii i psikhologii Chuvashii, 11(1), 57-76.
9. PolyakovaEO (2006). Borderline mental disorders in cardiology practice: diagnosis and treatment of problems [Pogranichnye psikhicheskie rasstroystva v kardiologicheskoy praktike: problemy diagnostiki i lecheniya]. Kardiologicheskiy vestnik, (2), 51-57.
10. SmulevichAB, SyrkinAL, DrobizhevMY, IvanovSV (2005). Psychocardiology [Psikhokardiologiya], 784.
11. StarostinaEG (2006). Anxiety and anxiety disorders in the practice of cardiology [Trevoga i trevozhnye rasstroystva v praktike kardiologa]. Kardiovaskulyarnaya terapiya i profilaktika, 5(3), 111-120.
12. Rational pharmacotherapy in psychiatric practice: a guidebook for medical practitioners [Ratsional’naya farmakoterapiya v psikhiatricheskoy praktike: rukovodstvo dlya praktikuyushchikh vrachey], 1080.
13. GuaianaG, BarbuiC, HotopfM (2007). Amitriptyline for depression. Cochrane database of systematic reviews, (3), СD004186, doi:https://doi.org/10.1002/14651858. CD004186.pub2
14. DemyttenaereK, HemelsME, Hudry J, Annemans L (2005). A cost-effectiveness model of escitalopram, citalopram and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clin. Therapeutics, 27(1), 111-123
15. PollockDG, Laghrissi-ThodeF, WagnerWR (2000). Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptylin treatment. J. Clin. Psychopharmacol., 20(2), 137-140.
